News · 26 weeks43+100%
2026-04-192026-10-11
Mix1890d
- Insider5(28%)
- SEC Filings4(22%)
- Other3(17%)
- Leadership3(17%)
- Analyst2(11%)
- Earnings1(6%)
Latest news
25 items- PRSTAAR Surgical Names Andrew Pilon as Vice President of Business DevelopmentAccomplished Ophthalmic Industry Executive and Clinician to Help Advance STAAR’s Strategic Partnerships, Innovation Opportunities, and Multi-Product Platform Strategy STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report to STAAR President and Chief Executive Officer Warren Foust and will work closely with the Company’s senior leadership team to capitalize on opportunities that support STAAR’s innovation strategy and expand the Company’s produc
- SECAmendment: STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K/A - STAAR SURGICAL CO (0000718937) (Filer)
- ANALYSTSTAAR Surgical upgraded by Stifel with a new price targetStifel upgraded STAAR Surgical from Hold to Buy and set a new price target of $31.00
- PRSTAAR Surgical Board Approves $50 Million Share Repurchase AuthorizationSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock. Under its buyback program, STAAR may repurchase shares in the open market, through privately negotiated transactions, by entering into structured repurchase agreements with third parties, by making block purchases, and/or pursuant to Rule 10b5-1 trading plans. The timing, manner, price, and amount of any repurchases under the prog
- PRSTAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision CorrectionShows 80% of Consumers Want to be Free of Glasses and Contacts, 58% Want a Reversible Option, and 59% Are Opposed to Laser Correction Safety Concerns and Procedure Fears Outrank Affordability as Primary Barriers to Laser Correction Consumer Research Uncovers the Demand Drivers Fueling Implantable Lens Growth as Laser Procedures Stagnate or Decline in Markets Surveyed STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration to
- PRSTAAR Surgical Names Former CEO David Bailey as Chief Commercial OfficerThe architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer. "David Bailey doesn't just know STAAR, he helped change the trajectory of the entire phakic IOL category," said Mr. Foust. "As our former President and CEO,
- INSIDERChief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERChief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERPresident and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- SECSEC Form 10-Q filed by STAAR Surgical Company10-Q - STAAR SURGICAL CO (0000718937) (Filer)
- SECSTAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - STAAR SURGICAL CO (0000718937) (Filer)
- PRSTAAR Surgical Reports Second Quarter 2026 ResultsNet Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026. Second Quarter 2026 Financial Overview Net sales of $93.5 million, up 111% Y/Y Net sales excluding China of $41.2 million, up 6.0% Y/Y China sales of $52.3 million up over 100%, 10% sequentially APAC sales up 189% Y/Y, ex-China sales up 7% Y/Y Am
- SECSTAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - STAAR SURGICAL CO (0000718937) (Filer)
- INSIDERPresident and CEO Foust Warren converted options into 20,787 shares and covered exercise/tax liability with 10,576 shares, increasing direct ownership by 13% to 86,556 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERChief Financial Officer & EVP Andrews Deborah J converted options into 34,742 shares and covered exercise/tax liability with 17,056 shares, increasing direct ownership by 95% to 36,339 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- PRSTAAR Surgical Appoints Warren Foust as President and Chief Executive OfficerDeborah Andrews appointed Executive Vice President and Chief Financial Officer STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that following an extensive global search, its Board of Directors (the "Board") has appointed Warren Foust as President and Chief Executive Officer and a new member of the Board of Directors, effective August 4, 2026. Mr. Foust joined STAAR in April 2023 and has served as President and Chief Operating Officer since March 2025 and as Interim Co-CEO, President & Chief Operating Officer since February 2026. Deborah An
- PRSTAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in combination with a shareholder letter for the second quarter ended July 3, 2026, on Wednesday, August 12, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical Second Quarter 2026 Financial Results Webcast Date: Wednesday, August 12, 2026 Time: 5:30 p.m. ET/ 2:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=lb5LeYQ0
- ANALYSTUBS initiated coverage on STAAR Surgical with a new price targetUBS initiated coverage of STAAR Surgical with a rating of Sell and set a new price target of $20.00
- PRSTAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expects to issue on August 12, 2026.Net sales for the second quarter of 2026 are expected to be in excess of $90 million, compared to net sales of $44.3 million for the second quarter of 2025.The Company delivered strong second quarter net sales, led by sequential growth in China, solid growth across the broader Asia-Pacific region, and double-di
- SECSEC Form S-8 filed by STAAR Surgical CompanyS-8 - STAAR SURGICAL CO (0000718937) (Filer)
- INSIDERSEC Form 4 filed by Director Wang Christopher Min Fang4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by Director Lebuhn Richard T.4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by Director Bradsher Neal C4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERDirector Butcher Arthur C converted options into 5,341 shares, increasing direct ownership by 127% to 9,549 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by Director Zhou Lilian Yansheng4 - STAAR SURGICAL CO (0000718937) (Issuer)
STAA FAQ
6 questionsWhat does STAAR Surgical Company do?
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related...Where does STAA stock trade?
STAAR Surgical Company (STAA) is listed on NASDAQ.What sector and industry is STAA in?
STAAR Surgical Company operates in the Health Care sector, Ophthalmic Goods industry.What are analysts saying about STAA?
STAAR Surgical Company has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $3100.00 price target on 2026-09-29. Recent price targets range from $1300.00 to $4000.00.What companies are similar to STAA?
Notable peers in the same industry include ALC (Alcon Inc.), COO (The Cooper Companies Inc.), BLCO (Bausch + Lomb Corporation), WRBY (Warby Parker Inc.), EYE (National Vision Holdings Inc.). Compare STAA side-by-side with any of them on Quantisnow.How can I track STAA on Quantisnow?
Quantisnow aggregates STAAR Surgical Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STAA to receive live email and push alerts on every new disclosure.